3rd Quarter - Report

ARENTFOX SCHIFF LLP for CSL BEHRING

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Orphan drug exclusion within the pharmaceutical tax in the Patient Protection and Affordable Care Act H.R. 2672 (Preserving Access to Orphan Drugs Act of 2011), all provisions

Foreign entity interest: CSL Limited, identified in the LD-1, is interested in U.S. tax policies that may affect the business of its subsidiary CSL Behring.

LobbyistCovered position, as disclosed
PHILIP ENGLISH —
LAURA EUGSTER DOYLE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2672 (112th)

Budget/Appropriations BUD

FY '11 and FY '12 Centers for Disease Control funding opportunities regarding Primary Immunodeficiency diseases research and programs FY '12 (S. 1599, and House bill) Labor/HHS/Education Appropriations regarding Centers for Disease Control funding opportunities for Primary Immunodeficiency diseases research and programs (Title II)

Foreign entity interest: CSL Limited, identified in the LD-1, is interested in the existence of funding for programs that may affect the business of its subsidiary CSL Behring.

LobbyistCovered position, as disclosed
PHILIP ENGLISH —
LAURA EUGSTER DOYLE —
DAN RENBERG New Member, Board of Directors, Ex-Im Bank; Leg., Dir. and Dep. Chief of Staff, Sen. Arlen Spector

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1599 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.